


## Sodalime Absorber versus Membrane CO<sub>2</sub> Filter Performance during Automated Closed-Circuit Anesthesia: A Case-Report

**Co-Authors:** S.A. Eerlings, M.D.<sup>1,2</sup>, R. Carette, M.D.<sup>1,2</sup>, G. Vandenbroucke, M.D.<sup>1</sup>, A. M. De Wolf, M.D.<sup>3</sup>, J. F.A. Hendrickx, M.D., Ph.D.<sup>1</sup>

Depts. of Anesthesiology of the OLV Hospital, Aalst, Belgium<sup>1</sup>, KU Leuven, Leuven, Belgium<sup>2</sup>, and Feinberg School of Medicine, Northwestern University, Chicago, IL, USA<sup>3</sup>

**Introduction:** Sodalime CO<sub>2</sub> absorbents are safe but not ideal for reasons of ecology (production and disposal), ergonomics (need to refill or replace), economy (discarded before used to full potential), and dust accumulation in sensitive machine parts. These issues are absent with the Memsorb™ (DMF Medical, Halifax, NS, Canada), a new device for gas-to-gas exchange and separation that uses technology similar to oxygenator membranes for cardiopulmonary bypass machines: the sweep flow determines CO<sub>2</sub> removal, and the sweep gas O<sub>2</sub> concentration the O<sub>2</sub> transfer across the fiber wall (which depends on the prevailing O<sub>2</sub> gradient across the fiber wall.) We present a case report in which we alternated the Memsorb™ with sodalime absorbent (Drägersorb 800+) during target-controlled closed-circuit anesthesia (TCCCA) with desflurane in O<sub>2</sub>/air with the Zeus IE (Dräger, Lübeck, Germany).

**Materials and Methods:** IRB approval and written informed consent were obtained in a 75 year old ASA PS III patient (73 kg, 164 cm) undergoing robotic abdominal wall hernia repair. After induction of anesthesia and intubation of the trachea, TCCCA with the Zeus IE was used with the following settings: target inspired O<sub>2</sub> (F<sub>I</sub>O<sub>2</sub>) 39% in O<sub>2</sub>/air; target end-expired (F<sub>A</sub>) desflurane 4.2%; controlled mechanical ventilation, adjusted to F<sub>A</sub>CO<sub>2</sub> 5.2-5.8%; and 5 cmH<sub>2</sub>O PEEP. An O<sub>2</sub>/air blender (Scanatron Technics, Affoltern-am-Albis, Switzerland) delivered the sweep gas (40% O<sub>2</sub>) to the inlet of the Memsorb™ canister. Sweep O<sub>2</sub>% was set 1% above target F<sub>I</sub>O<sub>2</sub>. The sweep flow was titrated to keep F<sub>I</sub>CO<sub>2</sub> ≤ 0.8%. Forty minutes after applying the CO<sub>2</sub> pneumoperitoneum (CO<sub>2</sub>PP), a Drägersorb800+ canister was inserted for 30 min, after which the Memsorb™ was inserted for the remainder of the procedure (see Figure 1). RUGloop (DEMED, Temse, Belgium) collected the following data: F<sub>I</sub>O<sub>2</sub>, F<sub>A</sub>desflurane, F<sub>I</sub>CO<sub>2</sub>, F<sub>A</sub>CO<sub>2</sub>, minute ventilation (MV); O<sub>2</sub> and air FGF; sweep flow; and cumulative desflurane usage (V<sub>des</sub>). A linear curve fit to the cumulative V<sub>des</sub> data during the last 50 min of the first Memsorb™ period, the 30 min Drägersorb800+ period, and the second (and final) Memsorb™ period. The initial maintenance phase (0-25min) and the first few min after changing the CO<sub>2</sub> scrubbers were excluded from analysis. Losses of O<sub>2</sub>, CO<sub>2</sub>, desflurane and N<sub>2</sub> (calculated as balance gas) from the Zeus' exhaust prior to switching to the Drägersorb800+ gases were calculated by measuring the amount of exhausted gases collected for 15 min into a 6 L breathing bag (volumetrically with 250 mL glass syringes) and by analyzing the gas content (M-CAiOV, GE, Madison, WI, USA).



### Results: See Figure 1.

F<sub>A</sub>desflurane and F<sub>I</sub>O<sub>2</sub> targets were maintained within a very narrow range. Liquid V<sub>des</sub> during TCCCA was higher with Memsorb™ (13.3 and 14.1 mL/h during the first and second run, respectively) than with Drägerorb800+ (7.7 mL/h). FGF was zero with Memsorb™ and 156 mL/min O<sub>2</sub> with the Drägerorb800+. Using the Memsorb™, a total of 162 mL/min gas lost via the Zeus' exhaust consisted of 52 mL/min O<sub>2</sub>, 1.6 mL/min CO<sub>2</sub>, 4.9 mL/min desflurane vapor (= 1.4 mL liquid/h) and 104 mL/min N<sub>2</sub>. This suggests 156+52 = 208 mL/min O<sub>2</sub> is transferred from the Memsorb™ to the breathing system (under the prevailing study conditions and assuming minimal leaks). Of the extra amount liquid desflurane used during Memsorb™ use (13.3-7.7=5.6, and 14.1-7.7=6.4 mL/h during run 1 and 2, respectively), 4.2 (=5.6-1.4) to 5.0 (=6.4-1.4) mL/h were lost via the Memsorb™ exhaust (approximately 1 mL/h liquid per 1% F<sub>A</sub>desflurane). F<sub>I</sub>CO<sub>2</sub> was 0 with Drägerorb800+ and ranged between 0.5-0.8% with Memsorb™ with the use of sweep flows ranging from 15 to 23 L/min.

**Discussion:** During TCCCA, Memsorb™ removes CO<sub>2</sub> well under conditions of high CO<sub>2</sub> elimination (adult patient with prolonged CO<sub>2</sub>PP). The small increase in F<sub>I</sub>CO<sub>2</sub> is inconsequential because its effect on F<sub>A</sub>CO<sub>2</sub> can easily be overcome by a small increase of minute ventilation. The amount of O<sub>2</sub> transferred from the Memsorb™ to the circle breathing system sufficed to cover patient O<sub>2</sub> consumption. Approximately 1 mL/h liquid per 1% F<sub>A</sub>desflurane is lost via the Memsorb™, with an additional small amount lost via the Zeus exhaust due to O<sub>2</sub> and N<sub>2</sub> transfer in excess of patient uptake from the Memsorb™ into the breathing circle.